Abnormal expression of CDK5 or its activators (particularly p35) due to amplification, mRNA upregulation or their combinations has been found in several human cancers, including cancers of the colon, breast, lung, ovary, prostate and pancreas, as well as melanoma and hematological malignancies. Here, CDK5 is linked to cancer.